Plain-English translation of NCT07763054 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This trial is testing , a medication designed to prevent serious fungal infections in people with blood cancers or those who have received stem cell transplants. Fungal infections are a major risk for patients whose immune systems are severely weakened by cancer treatment. Researchers want to see if giving this medication daily at a lower dose can protect patients safely and effectively.
Patients with certain blood cancers or those undergoing stem cell transplants have very weak immune systems and face a high risk of life-threatening fungal infections. While this medication is known to work, doctors are still figuring out the best dose and schedule to use it as a preventive treatment, so this study aims to test whether a daily low-dose approach works well.
You likely qualify if…
You likely don't qualify if…
You will receive the medication as an intravenous injection (through a vein) once daily at a dose of 50 mg. The study is observational, meaning doctors will monitor you during your regular cancer treatment to see how well the medication works and whether you experience any side effects. Your participation will continue throughout the period when you are at high risk for fungal infection, with your doctor assessing your progress and safety regularly.
AI-generated summary from trial data · Aug 14, 2026 · Not medical advice
China